Liam O'Brien

Liam O'Brien

Auto-generated profile, based on publicly available information

Liam O'Brien

Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
SBSreekumar Balan
Sreekumar Balan
LOLiam O’bRien
Liam O’bRien
APAnte Peros
Ante Peros
XWXuedi Wang
Xuedi Wang
IRIngrid Leal Rojas
Ingrid Leal Rojas
NBNina Bhardwaj
Nina Bhardwaj
A dendritic cell (DC)–based vaccine, Sipuleucel-T, remains the sole FDA-approved cancer vaccine. Despite their established safety and efficacy against cancers and infections in numerous trials, long-term clinical benefits have been modest. Most trials have employed DCs derived from blood monocytes, but emerging evidence underscores the unique role of conventional type 1 DCs (cDC1) in triggering potent antitumor immune responses and their intratumoral infiltration with favorable prognoses in many cancers. However, the scarcity of cDC1s in peripheral blood and the challenges in generating them in vitro have hindered a deeper understanding of their biology and their widespread application as cellular vaccines. In this study, we present a serum-free culture system capable of generating billions of human cDC1s from CD34+ progenitors derived from cord or peripheral blood. The system leverages the requirement of Notch signaling for cDC1 differentiation and generates DCs that closely resemble in vivo cDC1s, exhibiting functions including cellular antigen cross-presentation. This robust protocol enables the scalable production of cDC1s for both fundamental biological research and therapeutic applications.

23 June 2025 in OncoImmunology
Verified
Journal Article
Open access
LOLiam O’bRien
Liam O’bRien
IBIrina Buckle
Irina Buckle
ILIngrid M. Leal-Rojas
Ingrid M. Leal-Rojas
NRNikita Rosendahl
Nikita Rosendahl
KRKristen Radford
Kristen Radford
Prevention or reversal of T cell exhaustion is a major objective of cancer immunotherapy. However, few models exist to generate, characterize and modulate exhausted human T cells, particularly within solid tumors in vivo, which likely hampers the discovery and translation of novel therapeutics. In this study we describe a humanized mouse model where functional human CD8+ T cells specific for the tumor antigen NY-ESO-1 develop in vivo from human CD34+ hematopoietic stem cells genetically modified to express a HLA-A *0201-restricted NY-ESO-1 specific T cell receptor (TCR). HLA-A *0201+ NY-ESO-1+ expressing A375 melanoma tumors engrafted in these mice and were refractory to treatment with anti-PD-1 despite being infiltrated with NY-ESO-1 specific T cells. Tumor-Infiltrating Lymphocytes (TIL) upregulated tissue resident memory (TRM) markers CD103 and CD69 along with exhaustion markers PD-1, TIGIT, and CD39 relative to T cells from other organs. Further, TILs failed to secrete cytokines TNF and IFNγ following in vitro stimulation with conventional Type I Dendritic Cells (cDC1), indicative of terminal exhaustion. However, cDC1 stimulation of the terminally exhausted NY-ESO-1 specific TILs led to enhanced tumor killing that was associated with increased CD107a and Granzyme B expression that was restricted to a subset of CD226+ NY-ESO-1 specific TILs. These findings establish a novel platform to investigate T cell exhaustion in human tumors and suggest a role for cDC1 in enhancing terminally exhausted TIL cytotoxic function.


2 September 2025
Verified
Other
Open access
SBSreekumar Balan
Sreekumar Balan
LOLiam O’bRien
Liam O’bRien
APAnte Peros
Ante Peros
XWXuedi Wang
Xuedi Wang
IRIngrid Leal Rojas
Ingrid Leal Rojas
NBNina Bhardwaj
Nina Bhardwaj
A dendritic cell (DC)–based vaccine, Sipuleucel-T, remains the sole FDA-approved cancer vaccine. Despite their established safety and efficacy against cancers and infections in numerous trials, long-term clinical benefits have been modest. Most trials have employed DCs derived from blood monocytes, but emerging evidence underscores the unique role of conventional type 1 DCs (cDC1) in triggering potent antitumor immune responses and their intratumoral infiltration with favorable prognoses in many cancers. However, the scarcity of cDC1s in peripheral blood and the challenges in generating them in vitro have hindered a deeper understanding of their biology and their widespread application as cellular vaccines. In this study, we present a serum-free culture system capable of generating billions of human cDC1s from CD34+ progenitors derived from cord or peripheral blood. The system leverages the requirement of Notch signaling for cDC1 differentiation and generates DCs that closely resemble in vivo cDC1s, exhibiting functions including cellular antigen cross-presentation. This robust protocol enables the scalable production of cDC1s for both fundamental biological research and therapeutic applications.

2 September 2025
Verified
Other
Open access
SBSreekumar Balan
Sreekumar Balan
LOLiam O’bRien
Liam O’bRien
APAnte Peros
Ante Peros
XWXuedi Wang
Xuedi Wang
IRIngrid Leal Rojas
Ingrid Leal Rojas
NBNina Bhardwaj
Nina Bhardwaj
Enriched up- and down-regulated pathways between cDC1s generated using different culture methods

2 September 2025
Verified
Other
Open access
SBSreekumar Balan
Sreekumar Balan
LOLiam O’bRien
Liam O’bRien
APAnte Peros
Ante Peros
XWXuedi Wang
Xuedi Wang
IRIngrid Leal Rojas
Ingrid Leal Rojas
NBNina Bhardwaj
Nina Bhardwaj
Cytokine production and cross presentation capacity of cDC1 generated using different culture methods